Physician profile
Edward Strogach
NPI 1861499725
$5,567.07
in general payments reported to CMS, 2019-2025
32 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $203 · 2021: $794 · 2022: $1,071 · 2023: $914 · 2024: $918 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,281.62 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $641.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.19 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $532.16 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $430.04 | 2019-2023 | |
| Glaxosmithkline, LLC. | $387.77 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $235.84 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $198.01 | 2019-2025 | Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $191.65 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $134.41 | 2023-2025 | |
| Exact Sciences Corporation | $133.10 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $114.11 | 2019-2023 | Evenity, Prolia |
| Daiichi Sankyo INC. | $93.59 | 2024 | Injectafer |
| Sumitomo Pharma America, INC. | $85.41 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $67.18 | 2019-2024 | Heplisav-B |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.25 | 2019-2021 | |
| Astellas Pharma US INC | $57.68 | 2021-2025 | Myrbetriq, Veozah |
| Abbvie INC. | $55.73 | 2021-2022 | |
| Amarin Pharma, INC. | $46.06 | 2019-2022 | |
| Lundbeck LLC | $37.61 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $36.85 | 2022-2024 | Jynarque |
| Nevro Corp. | $32.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.32 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $21.85 | 2022 | |
| Philips North America LLC | $21.08 | 2024 | (Ck7) Extended Holter |
| Shield Therapeutics INC | $18.15 | 2023 | Accrufer |
| Teva Pharmaceuticals USA, INC. | $18.02 | 2022 | |
| Sanofi Pasteur INC. | $17.83 | 2022 | |
| Gilead Sciences, INC. | $15.53 | 2025 | |
| Intuity Medical INC | $13.13 | 2022 | |
| Phadia US INC. | $11.95 | 2022 | |
| Seqirus USA INC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Strogach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.